TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (OTC: TCBPY) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced receipt of a patent, granted from the European Patent Office (EPO), for targeting microbial, oncological, and viral indications using modified gamma delta T cells.